1p/19q-driven prognostic molecular classification for high-grade oligodendroglial tumors
- PMID: 25151507
- DOI: 10.1007/s11060-014-1593-0
1p/19q-driven prognostic molecular classification for high-grade oligodendroglial tumors
Abstract
The subjectivity in pathological diagnosis of anaplastic oligoastrocytoma (AOA) and uncertainty in designation of glioblastoma with oligodendroglioma component (GBMO) were two major dilemmas which puzzled neuro-pathologists and neurosurgeons. The present study was designed to project a molecular classification scheme based on the status of chromosome 1p and 19q. Patients (n = 117) with histological diagnosis of primary high-grade oligodendroglial tumors (HGOs) enrolled in the study. Fluorescence in situ hybridization (FISH) for chromosomes 1p and 19q was performed. Univariate analysis showed that higher tumor grade, 1p/19q maintenance and 1q/19p co polysomy were confirmed as risk factors in HGOs (P < 0.01). Accordingly, patients with HGOs were divided into four subtypes which conferred remarkably distinct prognosis based on the number of risk factors (0 risk factor: HGOs-1, 1 risk factor: HGOs-2, 2 risk factors: HGOs-3, 3 risk factors: HGOs-4). Cox regression model revealed that the tumor grade was no longer independently associated with survival, while the molecular classification scheme showed a marked prognostic significance (HR = 0.359, 95 % CI 0.261-0.494, P < 0.001 for progression-free survival (PFS); HR = 0.393, 95 % CI 0.283-0.546, P < 0.001 for overall survival (OS)). The classification scheme incorporating traditional pathology with molecular information can be served as a supplement of the current WHO classification system and contribute to the personalized treatment decision-making.
Similar articles
-
Co-polysomy of chromosome 1q and 19p predicts worse prognosis in 1p/19q codeleted oligodendroglial tumors: FISH analysis of 148 consecutive cases.Neuro Oncol. 2013 Sep;15(9):1244-50. doi: 10.1093/neuonc/not092. Epub 2013 Jul 16. Neuro Oncol. 2013. PMID: 23861470 Free PMC article.
-
Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951.Neuro Oncol. 2009 Dec;11(6):737-46. doi: 10.1215/15228517-2009-011. Neuro Oncol. 2009. PMID: 19224764 Free PMC article. Clinical Trial.
-
Short-term survivors in glioblastomas with oligodendroglioma component: a clinical study of 186 Chinese patients from a single institution.J Neurooncol. 2014 Jan;116(2):395-404. doi: 10.1007/s11060-013-1311-3. Epub 2013 Nov 22. J Neurooncol. 2014. PMID: 24264532 Free PMC article.
-
Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma.Arch Pathol Lab Med. 2007 Feb;131(2):242-51. doi: 10.5858/2007-131-242-CAOQLA. Arch Pathol Lab Med. 2007. PMID: 17284109 Review.
-
Oligodendrogliomas: molecular biology and treatment.Oncologist. 2009 Feb;14(2):155-63. doi: 10.1634/theoncologist.2008-0248. Epub 2009 Jan 31. Oncologist. 2009. PMID: 19182242 Review.
Cited by
-
Supratentorial high-grade astrocytoma with leptomeningeal spread to the fourth ventricle: a lethal dissemination with dismal prognosis.J Neurooncol. 2019 Apr;142(2):253-261. doi: 10.1007/s11060-018-03086-8. Epub 2019 Jan 2. J Neurooncol. 2019. PMID: 30604394
-
Extent of resection and survival for oligodendroglioma: a U.S. population-based study.J Neurooncol. 2019 Sep;144(3):591-601. doi: 10.1007/s11060-019-03261-5. Epub 2019 Aug 12. J Neurooncol. 2019. PMID: 31407129
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources